CXCL5 and prostate cancer: TRAIL although could motivate the expression of prometastatic molecules, such as CXCL5/ENA-78 and IL-6 in prostate cancer cells, this influence could be defeated by combination therapy with an AKT inhibitor (Mohr et al., 2019).